Press release from Emotra AB (publ)
Göteborg, March 13, 2017

European Commission Horizon 2020 – application rejected

The European Commission, EC, has rejected Emotra's application, submitted in January 2017, for approximately 3 MEUR, intended for three purposes: First of all to finance EUDOR-Y, a clinical multi-centre study on young people, secondly to develop EDOR® Interconnect, and thirdly to further develop our hardware and software solutions. Similar to last time, the application cleared the threshold for all the important criteria and was awarded a second "Seal of Excellence". We will be submitting a new, revised application as soon as possible. It is quite normal for several applications to be rejected before the EC grants one. The fact that this application was rejected does not affect the Company's market launch plans.

After completing our feasibility study, funded by the EC, the Company submitted its application on October 7, 2016 for appr. 3 MEUR in funding, which was aimed at financing our international clinical EUDOR-Y study on suicide among young people, as well as to develop EDOR® Interconnect, a global communication platform, and further develop both our hardware and our software.

The EC informed us of their rejection at the end of November. A new application was submitted on January 13, 2017, and the Company has now been notified that this application was also denied. However, the fact that Emotra's application was once again awarded a "Seal of Excellence" shows that the European Commission recommends that our project be granted financial support through EU funding and/or other sources. This award also shows that the application has cleared the threshold for three important criteria: "Excellence", "Impact" and "Quality and Efficiency of implementation".

We will be submitting a new, revised application as soon as possible.

Emotra's application was aimed at investigating the possibility of widening the indication spectrum for EDOR® to also encompass children and young people up to 20 years of age. A clinical multi-centre study, EUDOR-Y, exclusively for children and young people from 12 to 20 years of age has now been planned. Broadening the indication range for EDOR® to encompass younger people has long-term strategic importance for Emotra. This would lead to an increase in EDOR®'s future market, but most importantly it would mean finding a tool with which to identify depressed European youths who are at risk of committing suicide. More and more young Europeans are committing suicide, with catastrophic consequences for their families and loved ones.

Our application also included funding to further develop the hardware and software, and to develop "EDOR® Interconnect", a global communication platform that will facilitate Emotra's communication with clinical departments and serve them in different parts of the world. A large number of leading international youth clinics, as many as 26 centres located in a large number of countries, have registered their interest in participating in EUDOR-Y. This is

a clear sign of how important the psychiatric profession feels it is to evaluate EDOR® for testing of depressed young people. From the Company's viewpoint, this means that we need to start EUDOR-Y as soon as we have secured financing.

The market introduction of EDOR® will commence directly after conclusion of the analysis of our adult study EUDOR-A, which encompasses patients 18 years and older. Naturally, our market launch is based on the study results meeting all of the Company's and the clinics' expectations. On March 29–30, we will be holding a consensus meeting in Rome with all of the involved clinics. The aim of this meeting is to carefully analyse the results of the study and investigate the possibilities of a future launch. On April 2–4, we aim to present our results at the European Psychiatric Association's (EPA) international conference in Florence, Italy.

For further information about the Company, please contact:
Claes Holmberg, CEO, telephone: +46 708 25 45 47, E-mail: claes@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation and the Securities Market Act. This information was submitted for publication on March 13, 2017 under the above contact's supervision.

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*